Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric A Singer

Showing results (231-240 of 253) with videos related to

Pageof 26
Sort By:
Urology|April 20, 2021
Preventing Prostate Biopsy Complications: to Augment or to Swab?Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology|September 7, 2021
EDITORIAL COMMENTLydia Glick, Sage A Vincent, Danielle Squadron, et al.
The Lancet. Oncology|May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsCaroline E Wheeler, Samuel S Coleman, Rebecca Hoyd, et al.
Urologic Oncology|August 8, 2025
Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancerMatthew Ho, Alon Lazarovich, Ragheed Saoud, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Journal for Immunotherapy of Cancer|September 17, 2025
Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escapeBing-Jian Feng, Wendy Kohlmann, David A Nix, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Cancer Research Communications|July 17, 2024
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint InhibitorsCaroline E Dravillas, Samuel S Coleman, Rebecca Hoyd, et al.
Pageof 26

Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Urology|April 20, 2021
Preventing Prostate Biopsy Complications: to Augment or to Swab?Lydia Glick, Sage A Vincent, Danielle Squadron, et al.
Urology|September 7, 2021
EDITORIAL COMMENTLydia Glick, Sage A Vincent, Danielle Squadron, et al.
The Lancet. Oncology|May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsCaroline E Wheeler, Samuel S Coleman, Rebecca Hoyd, et al.
Urologic Oncology|August 8, 2025
Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancerMatthew Ho, Alon Lazarovich, Ragheed Saoud, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Journal for Immunotherapy of Cancer|September 17, 2025
Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escapeBing-Jian Feng, Wendy Kohlmann, David A Nix, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Cancer Research Communications|July 17, 2024
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint InhibitorsCaroline E Dravillas, Samuel S Coleman, Rebecca Hoyd, et al.
Pageof 26